Drug intelligence / Profile preview

n-2-fluorenylacetamide

Development stage
Unknown
Modality
Small Molecules
Administration
Not Intended For Administration In Humans Or Animals Except As A Laboratory Reagent (typically Parenteral In Animal Research)
01

Overview

N-2-fluorenylacetamide, also known as 2-acetylaminofluorene (2-AAF), is a polycyclic aromatic compound historically studied for its profound carcinogenic and mutagenic properties[2][5][6]. This small molecule is used primarily in laboratory research as a model genotoxic carcinogen to induce liver cancer (hepatocarcinogenesis) and other tumors in animal models, notably rodents[2][5]. Its mechanism of action involves metabolic activation by cytochrome P450 enzymes (notably CYP1A2) to form N-hydroxy-2-AAF and other reactive intermediates, which produce DNA adducts leading to mutagenesis and carcinogenesis[5]. It is not used clinically and is handled only for research as a positive control in carcinogenicity studies or mechanistic toxicology[2][5].

Other names
2-acetamidofluorene2-acetylaminofluoreneN-(2-fluorenyl)acetamideN-2-fluorenylacetamideN2-fluorenylacetamideN 2-fluorenylacetamide2-fluorenylacetamide
02

Targets

DNACYP1A2 (Cytochrome P450 1A2)

Beyond the preview

Go deeper on n-2-fluorenylacetamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on n-2-fluorenylacetamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call